The University of Toledo

Eric G. Sahloff

Eric G. Sahloff, Pharm.D. Associate Professor of Clinical Pharmacy Department of Pharmacy Practice 419.383.1962 HEB114B esahlof@utnet.utoledo.edu

Dr. Sahloff received his bachelors of science in pharmacy and doctor of pharmacy degrees from The University of Toledo. He completed a specialty residency in critical care/infectious diseases at St. Vincent Mercy Medical Center in Toledo, OH. He went on to complete a fellowship in critical care/infectious diseases at The University of Toledo.

Dr. Sahloff coordinates and lectures in Drug Literature Evaluation and the Seminar series, and also lectures in the Infectious Diseases and Gastrointenstinal Pharmacotherapy (PPT) courses with a focus in the area of HIV/AIDS and Hepatitis.

Dr. Sahloff actively participates in a multidisciplinary infectious diseases clinic which specializes in HIV/AIDS. Research interests include pharmacokinetic/pharmacodynamics of antiretroviral agents and HIV/AIDS pharmacotherapy.

Dr. Sahloff is currently a member of the American Association of Colleges of Pharmacy, American Society of Microbiology, and Society of Infectious Diseases Pharmacists.  Dr. Sahloff is credentialled as an HIV Expert by the American Academy of HIV Medicine.

Recent Publications:

Peeters MJ, Sahloff EG, Stone G. Reliability and validity in performance-based evaluation: a 2-year experience in PharmD oral presentations using multiple faculty evaluators and a standardized rubric. Am J Pharm Ed, 2010;74:Article 171. http://www.ajpe.org/aj7409/aj7409171/aj7409171.pdf

Pinto S, Sahloff EG, Ramasamy A. Evaluating the validity and reliability of a modified survey to assess patient satisfaction with mail-order and community pharmacy settings. J Pharm Pract 2009. Published online: http://jpp.sagepub.com/cgi/rapidpdf/0897190009334329v1

Yost R, Pasquale TR, Sahloff EG. Maraviroc: the first approved CCR5-antagonist for the management of HIV-infection. Am J Health Syst Pharm 2009;66: 715-726.

Bhumbra N, Sahloff EG, Oehrtman S, Horner J.  Exogenous Cushings syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir. Ann Pharmacother 2007; 41:1306-09. DOI 10.1345/aph.1K075.

Sahloff EG, Duggan JM.  Clinical outcomes associated with concomitant use of atazanavir and proton-pump inhibitors. Ann Pharmacother 2006; 40:1731-36.

Duggan JM, Sahloff EG, Moudgal VV. Use of highly active antiretroviral therapy in patients with renal insufficiency. Pharmacotherapy 2005;25:698-708.

Sahloff EG.  Current issues in the development of a vaccine to prevent human immunodeficiency virus: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2005;25:741-747.